Home
Resources
Publications
5-Bromo-2'-deoxyuridine Induced Effluvium via p53-mediated CD326-positive Keratinocyte Apoptosis in C57BL/6 Mice

5-Bromo-2'-deoxyuridine Induced Effluvium via p53-mediated CD326-positive Keratinocyte Apoptosis in C57BL/6 Mice

Kyung-Jun Uh, Woo-Sung Hwang, Ji-Hyun Bae, Da-Eun Jang, Su-Cheong Yeom

J Dermatol. 2017 Feb;44(2):180-185.

PMID: 27543435

Abstract:

Anagen effluvium develops because of disturbances in the hair follicle cycle, leading to acute and severe hair loss in humans. The objective of this study was to establish a mouse model of anagen effluvium by 5-bromo-2'-deoxyuridine (BrdU) treatment, and evaluate the pathological changes and underlying mechanisms. We treated 9-10-day-old pups and 3-7-week-old C57BL/6 mice with BrdU. After successfully inducing hair loss in the neonatal pups, microscopic, immunohistochemical and flow cytometry analyses were conducted. BrdU induced early onset alopecia in neonates and caused epidermal thickening and hair shaft breakage. BrdU appeared to incorporate the CD326-positive keratinocyte layer and induced p53-related apoptosis. Keratinocyte apoptosis caused immune cell infiltration in the dermal region; M2 macrophages and neutrophils were dominant. The BrdU-induced hair loss was dose-dependent, and alopecia was visible at a dose range of 25-200 μg/g bodyweight. The BrdU-induced anagen effluvium mouse model is novel and easily established by administrating four simple BrdU injections to pups; these mice showed synchronized onset of alopecia symptoms with little individual variation. Moreover, this model showed an alopecia phenotype similar to that of human anagen effluvium with acute, severe and widespread hair loss.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP59143	5-Bromo-2′-deoxyuridine		59-14-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: